Stockscreener 앱 받기
190.02
8.54%
14.95
시장 영업 전:
188.98
-1.04
-0.55%
전일 마감가:
$175.07
열려 있는:
$178.88
하루 거래량:
1.67M
Relative Volume:
2.21
시가총액:
$4.00B
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-20.72
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
+261.81%
1개월 성능:
+350.07%
6개월 성능:
+437.69%
1년 성능:
+159.84%
1일 변동 폭
$176.61
$191.91
1주일 범위
$52.62
$205.89
52주 변동 폭
$26.70
$205.89
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
190.02 | 3.69B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.27 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
474.00 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.34 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
834.75 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.31 | 35.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Does Praxis Precision Medicines Inc. qualify in momentum factor screening2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.Market Movement Recap & Community Driven Trade Alerts - newser.com
Rapid Rise of PRAX: Essential Tremor Breakthrough - StocksToTrade
Praxis Precision Medicines, Inc. Announces FDA Type B Meeting for Ulixacaltamide - TradingView
12 Reddit Stocks That Will Go to the Moon - Insider Monkey
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Stop Loss & Verified Stock Trade Ideas - newser.com
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Published on: 2025-10-20 08:35:46 - newser.com
Wedbush lifts Praxis Precision Medicines PT; shares down - TradingView
Largest borrow rate increases among liquid names - TipRanks
Published on: 2025-10-20 07:35:45 - newser.com
Wedbush Boosts Price Target on Praxis Precision Medicines to $73 From $33, Keeps Underperform Rating - MarketScreener
Praxis Precision Medicines Announces Underwritten Offering - TradingView
Praxis surges after late-stage trial success for movement disorder therapy - MSN
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
Is Praxis Precision Medicines Inc. stock undervalued vs historical averagesPortfolio Return Summary & Safe Capital Growth Trade Ideas - nchmf.gov.vn
Praxis Precision Medicines (PRAX) Is Up 256.7% After Positive Phase 3 Results for Essential Tremor Drug - simplywall.st
Is Praxis Precision Medicines Inc. stock a buy on dipsJuly 2025 Fed Impact & Verified Stock Trade Ideas - nchmf.gov.vn
Major Investment Alert: Adage Capital’s Bold Move in Praxis Precision Medicines! - TipRanks
Is Praxis Precision Medicines Inc. stock cheap at current valuationJuly 2025 Sector Moves & Long-Term Safe Investment Ideas - nchmf.gov.vn
PRAX underwritten deal: $157/share, warrants; $567M net proceeds - Stock Titan
PRAX prices common stock and pre-funded warrants; proceeds ~$493.0M - Stock Titan
Praxis Precision Medicines, Inc.Common Stock (NQ: PRAX - FinancialContent
Can Praxis Precision Medicines Keep Climbing? - timothysykes.com
[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity - Stock Titan
Praxis Shares Skyrocket: Too Late to Buy? - StocksToTrade
Praxis Precision Medicines: A New High? - timothysykes.com
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - Benzinga
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results - Insider Monkey
Ulixacaltamide Trial Success Propels PRAX - StocksToTrade
Boston biotech raises $525M after stock triples on late-stage drug trial results - The Business Journals
Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? - Yahoo Finance
Praxis Precision Medicines (PRAX) Stock Soars After Essential Tremor Drug Success - parameter.io
Praxis Precision Medicines, Inc. (PRAX) Stock: Soars 183% Following $525M Public Offering Announcement - parameter.io
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Deutsche Bank Boosts Price Target on Praxis Precision Medicines to $280 From $65, Keeps Buy Rating - MarketScreener
Praxis Precision Medicines extends rally after $525 mln stock sale - TradingView
Praxis: Back From The Dead, Ulixacaltamide Returns In Essential Tremor With Caveats (PRAX) - Seeking Alpha
Praxis Precision Medicines Reaches Analyst Target Price - Nasdaq
Praxis Precision Medicines prices $525 million public offering By Investing.com - Investing.com Nigeria
Why Praxis Precision Medicines Stock Skyrocketed - TipRanks
Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win - Stocktwits
Praxis Precision Medicines Prices $525 Million Share Offering - MarketScreener
Praxis Precision Medicines prices $525 million public offering - Investing.com India
Praxis Precision Medicines (PRAX) Aims to Raise $525M Through Pu - GuruFocus
Praxis Precision Medicines prices $525M public offering - MSN
A Look at Praxis Precision Medicines (PRAX) Valuation Following Positive Phase 3 Results in Essential Tremor - simplywall.st
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering - Investing News Network
Praxis Precision Medicines Announces Pricing of $525 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
$525M Offering — Praxis Precision Medicines Prices Common Stock at $157 per Share - Stock Titan
Praxis Precision Medicines stock soars as Oppenheimer raises price target on trial success - Investing.com Philippines
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.32%
1.34%
자본화:
|
볼륨(24시간):